A therapy mixture with Yervoy (ipilimumab) plus Opdivo (nivolumab), in contrast with standard-of-care therapies, considerably improved 12-month survival in sufferers with non-clear cell...
Sufferers with high-risk muscle-invasive urothelial carcinoma (MIUC) who underwent radical surgical procedure skilled notable enhancements in disease-free survival (DFS, the time a affected...
Sarclisa, a brand new drug, has been authorized by the FDA for treating newly recognized, transplant-ineligible a number of myeloma sufferers, demonstrating a...
